PTO/SB/08a (08-03)

U.S.Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Approved for use through 07/31/2006. OMB 0651-0031 695, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Under the Paper & Reduction Act Complete if Known Tubstitute for form 1449A/PTO **Application Number** 10/555,664 INFORMATION DISCLOSURE Filing Date November 4, 2005 STATEMENT BY APPLICANT Peter ASSAF et al First Named Inventor 1614 Art Unit (use as many sheets as necessary) Examiner Name Not Yet Assigned Attorney Docket Number 30724 2 of 1 Sheet **U.S. PATENT DOCUMENTS** Pages, Columns, Lines, Where Name of Patentee or **Publication Date** Cite Document Number Examiner Relevant Passages or Relevant Applicant of Cited Document MM-DD-YYYY No. 1 Initials* Figures Appear Number-Kind Code² (if known) 06-23-2005 US-2005/0137191 Thatcher et al. US-6,310,052 Thatcher et al. 10-30-2001 2 Thatcher et al. US-5,883,122 03-16-1999 3 09-15-1998 Thatcher et al. US-5,807,847 Thatcher et al. 11-28-2002 US-2002/0177622 Thatcher et al. US-6,916,835 07-12-2005 6 US-09/473,713 12-29-1999 Thatcher et al. Goodman et al. 04-11-1995 US-5,404,871 Goodman et al. US-5,542,410 06-6-1996

> 02-23-1999 11-16-1999

> 04-24-2001

07-31-2001

05-20-2003

03-3-2003

10-28-2003

11-25-2003

US-5,874,063

US-5,983,956

US-6,221,398

US-6,268,533

US-6,566,324

US-6,571,790

US-6,637,430

US-6,652,323

11

12

13

14

15

16

17

Briggner et al.

Trofast

Jakupovic et al.

Nadel et al.

Weinstein

Voges et al

Yanda

Gao et al.

		FOREIGN	PATENT DOC	UMENTS		
Examiner Initials*	Cite No.	Foreign Patent Documents Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	7 6
/S.L./	18	PCT WO 01/49275	07-12-2001	Thatcher et al.		
_/ _/	19	PCT WO 03/086282	10-23-2003	Fang et al.	•	\perp
1/	20	PCT WO 00/30614	02-2-2000	Bisrat et al.		\perp
V	21 PCT WO 99/55319 04-4-1999		Cooper		\vdash	
	 					上
Examine Signatur		/Sun Jae Loewe/		Date Considered	12/28/2007	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WiPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Recorgion Apper no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449A/PTO **Application Number** 10/555,664 INFORMATION DISCLOSURE Filing Date November 4, 2005 STATEMENT BY APPLICANT First Named Inventor Peter ASSAF et al 1614 Group Art Unit (use as many sheets as necessary) Not Yet Assigned Examiner Name Attorney Docket Number 30724 2 Of | 2 Sheet OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Examiner Cite item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), Υ^2 No.1 Initials publisher, city and/or country where published. Kumar et al. "Design, Synthesis, and Evaluation of α-Ketoheterocycles as Class C β-22 /S.L./ Lactamase Inhibitors", Bioorganic & Medicinal Chemistry, 9: 2035-2044, 2001. Cavicchi et al. "Inhibition of Inducible Nitric Oxide Synthase in the Human Intestinal 23 Epithelial Cell Line, DLD-1, by the Inducers of Heme Oxygenase 1, Bismuth Salts, Heme, and Nitric Oxide Donors", GUT, 47(6): 771-778, 2000. Abstract. Salas et al. "Nitric Oxide Supplementation Ameliorates Dextran Sulfate Sodium-24 Induced Colitis in Mice", Laboratory Investigation, 82(5): 597-607, 2002. Abstract, P.602, Col. 1, Lines 3-19. Ueda et al. "Structure-Activity Relationships of 2-Aminothiazole Derivatives as 25 Inducible Nitric Oxide Synthase Inhibitor", Chemical & Pharmaceutical Bulletin, 52(5): 634-637, 2004. Abstract, P.634, Col.2, Last Line - P.635, Col.1, Line 2, Table 2, Expls. 5a, 5b, 7, P.636, Col.1, Lines 17-18, 25-39. Münzel et al. "Evidence fpr Enhanced Vascular Superpxide Anion Production", The 26 Journal of Clinical Investigation, 95: 187-194, 1995. Chung et al. Identification of the Subcellular Site for Nitroglycerin Metabolism to 27 Nitric Oxide in Bovine Coronary Smoth Muscle Cells", The Journal of Pharmacology and Experimental Therapeutics, 253(2): 614-619, 1990. McGuire et al. "Inhibition of NADPH-Cytochrome P450 Reductase and Glyceryl 28 Trinitrate Biotransformation by Diphenyleneidononium Sulfate", Biochemical Pharmacology, 56: 881-893, 1998. Needleman et al. "Sulfhydryl Requirement for Relaxation of Vascular Smooth 29 Muscle", The Journal of Pharmacology and Experimental Therapeutics, 187(2): 324-331, 1973. Bueb et al. "Natural Polyamines Stimulate G-Proteins", Biochemical Journal, 282: 30 545-550, 1992. Loscalzo "N-Acetylcysteine Potentiates Inhibition of Platelet Aggregation by 31 Nitroglycerin", Journal of Clinical Investigation, 76: 703-708, 1985. Kurz et al. "Nitroglycerin Metabolism in Vascular Tissue: Role of Glutathione S-32 Transferases and Relationship Between NO and NO2-Formation", Biochemical Journal, 292: 545-550, 1993.

		T	
Signature	/Sun Jae Loewe/	Considered	12/28/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

^{1.} Applicant's unique citation designation number (optional). 2. Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14, this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.